Avadel's US Application In Sleep Disorder Accepted For Review

The FDA has accepted Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) marketing application seeking approval for FT218 for review. FT218 is a formulation to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The FDA has assigned the target action date of October 15. Narcolepsy is a chronic sleep disorder characterized...